TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05756322: The Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias

Sponsor: Lin BioScience, Inc · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 90 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$1,693,200

Rescue Site Savings

+$1,128,800

Unlock Full NCT05756322 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05756322 Rescue Dossier →